|February 15, 2023
|Targeting distinct metabolic vulnerabilities of aggressive renal cell carcinoma variants
|The University of Texas M.D. Anderson Cancer Center
|Principal Investigator/Program Director
|Niki Zacharias Millward
|Kidney and Renal Pelvis
Renal medullary carcinoma (RMC) and fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) are rare but highly aggressive kidney cancers, with most patients dying within the first 5 years after diagnosis of metastatic disease in FH-deficient RCC, while less than 5% of patients with RMC survive longer than 36 months from diagnosis. Currently, there is no curative therapy for these two cancers. Both cancers occur in younger patients, with the mean age at diagnosis of 40 years for FH-deficient RCC and 28 years for RMC. Effective treatment strategies are desperately needed in these two highly lethal cancers. Bevacizumab plus erlotinib is a preferred first-line therapy for FH-deficient RC...